share_log

Abbott Laboratories | 8-K: Abbott Reports Second-Quarter 2024 Results and Raises Full-Year Guidance

Abbott Laboratories | 8-K: Abbott Reports Second-Quarter 2024 Results and Raises Full-Year Guidance

雅培 | 8-K：雅培公佈2024年第二季度業績並上調全年預期
美股SEC公告 ·  2024/07/18 19:41

牛牛AI助理已提取核心訊息

Abbott reported Q2 2024 sales of $10.4 billion, with organic sales growth of 9.3% in the underlying base business excluding COVID-19 testing. Medical Devices led growth with 12.1% organic increase, driven by strong performance in Diabetes Care where FreeStyle Libre sales reached $1.6 billion, up 20.4% organically. The company delivered adjusted EPS of $1.14, exceeding expectations.Abbott strengthened its portfolio with multiple regulatory approvals, including FDA approval of Esprit BTK system for peripheral artery disease and CE Mark for AVEIR dual chamber leadless pacemaker. The company also received FDA clearance for two new over-the-counter continuous glucose monitoring systems - Lingo and Libre Rio.Based on strong performance, Abbott raised its full-year 2024 adjusted EPS guidance to $4.61-$4.71 and narrowed organic sales growth guidance excluding COVID-19 testing to 9.5-10.0%. The company maintained its strong dividend track record with its 402nd consecutive quarterly dividend, marking 52 years of consecutive dividend increases.
Abbott reported Q2 2024 sales of $10.4 billion, with organic sales growth of 9.3% in the underlying base business excluding COVID-19 testing. Medical Devices led growth with 12.1% organic increase, driven by strong performance in Diabetes Care where FreeStyle Libre sales reached $1.6 billion, up 20.4% organically. The company delivered adjusted EPS of $1.14, exceeding expectations.Abbott strengthened its portfolio with multiple regulatory approvals, including FDA approval of Esprit BTK system for peripheral artery disease and CE Mark for AVEIR dual chamber leadless pacemaker. The company also received FDA clearance for two new over-the-counter continuous glucose monitoring systems - Lingo and Libre Rio.Based on strong performance, Abbott raised its full-year 2024 adjusted EPS guidance to $4.61-$4.71 and narrowed organic sales growth guidance excluding COVID-19 testing to 9.5-10.0%. The company maintained its strong dividend track record with its 402nd consecutive quarterly dividend, marking 52 years of consecutive dividend increases.
雅培報告稱2024年第二季度銷售額爲104億美金，基本業務（不包括COVID-19檢測）的有機銷售增長爲9.3%。醫療設備帶動了增長，有機增長率爲12.1%，這得益於糖尿病護理的強勁表現，FreeStyle Libre的銷售額達到16億美金，有機增長20.4%。公司每股收益（EPS）調增至1.14美金，超出預期。雅培通過多個監管批准加強了其產品組合，包括FDA對外周動脈疾病Esprit BTk系統的批准以及AVEIR雙腔無導線心臟起搏器的CE標記。公司還獲得FDA對兩個新的非處方連續血糖監測系統——Lingo和Libre Rio的批准。基於強勁的表現，雅培將2024年全年調增的每股收益（EPS）預期提高至4.61-4.71美金，並將不包括COVID-19檢測的有機銷售增長預期縮小至9.5-10.0%。公司維持了強勁的股息記錄，完成了第402次連續季度股息，標誌着連續52年的股息增長。
雅培報告稱2024年第二季度銷售額爲104億美金，基本業務（不包括COVID-19檢測）的有機銷售增長爲9.3%。醫療設備帶動了增長，有機增長率爲12.1%，這得益於糖尿病護理的強勁表現，FreeStyle Libre的銷售額達到16億美金，有機增長20.4%。公司每股收益（EPS）調增至1.14美金，超出預期。雅培通過多個監管批准加強了其產品組合，包括FDA對外周動脈疾病Esprit BTk系統的批准以及AVEIR雙腔無導線心臟起搏器的CE標記。公司還獲得FDA對兩個新的非處方連續血糖監測系統——Lingo和Libre Rio的批准。基於強勁的表現，雅培將2024年全年調增的每股收益（EPS）預期提高至4.61-4.71美金，並將不包括COVID-19檢測的有機銷售增長預期縮小至9.5-10.0%。公司維持了強勁的股息記錄，完成了第402次連續季度股息，標誌着連續52年的股息增長。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間